OCUL - Company ID 0001393434
The table below shows OCULAR THERAPEUTIX, INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$65.99M | -$44.67M | -$33.89M | -$19.97M | -$18.60M | -$17.36M |
| Capital expenditure | $4.66M | $1.93M | $255.00K | $3.38M | $276.00K | $158.00K |
| Investing cash flow | -$4.66M | -$1.93M | -$255.00K | -$3.38M | -$276.00K | -$158.00K |
| Dividends paid | - | - |
OCULAR THERAPEUTIX, INC reported operating cash flow of -$204.88M for fiscal year 2025. That is down 52.1% from -$134.68M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$34.00M (FY 2016) to -$204.88M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $294.00K | $4.18M | $321.22M | $78.00K | $129.00K | -$1.16M |